Tarsus Pharmaceuticals has forged a takeover deal with Alkeus Pharmaceuticals worth up to $800m, adding a Stargardt disease asset with possible “blockbuster potential” to its pipeline and bolstering its standing in the ophthalmology space.
As per the agreement, Tarsus will hand over around $450m to Alkeus upfront, including $270m in cash and $180m in Tarsus stock, as well as up to $350m in regulatory and commercial milestones to absorb Alkeus’ range of ophthalmic pipeline assets.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
At the centrepiece of the deal is once-daily oral therapy gildeuretinol, which Alkeus is currently evaluating in late-stage trials for the rare inherited eye disorder, Stargardt disease. The drug, once dubbed ALK-001, is now in the Phase III NORTHSTAR study (NCT07419334), which dosed its first patient in June 2026. The company expects topline data from this trial to debut in the second half of 2029.
If approved, gildeuretinol could become one of the first drugs to reach the Stargardt market, as a therapy is yet to secure the regulatory greenlight in this indication. Stargardt disease impacts around one in 10,000 individuals and presents as the progressive loss of central vision linked to a buildup of toxic yellow-brown pigment, lipofuscin, on the centre of the retina.
Alkeus designed gildeuretinol to address the underlying disease biology of Stargardt by reducing the formation of toxic vitamin A dimers, while preserving the visual cycle.
In a statement, Tarsus noted that its Alkeus acquisition would constitute an “important step” in the company’s strategy to become a key player in the eye care space – building on its prior $565m takeover of iRenix Medical and its ocular antiseptic candidate, IRX-101.
Stargardt race to market remains tight
With gildeuretinol potentially joining Tarsus’ pipeline – provided the Alkeus takeover is finalised – the company could be poised to enter the race to market in Stargardt disease, as several companies advance their drugs for the condition through the late stages of development.
Currently, the frontrunner is Belite Bio, which is already vying for its Stargardt therapy, tinlarebant’s US approval via the rolling submission of a new drug application (NDA), which the biotech initiated back in April 2026. Belite began this process after the retinol-binding protein 4 (RBP4) antagonist posted a late-stage win in the Phase III DRAGON study (NCT05244304).
Also in the running to secure a potential spot on the Stargardt market is Ocugen, which is advancing its gene therapy, OCU410ST, through a late-stage study. In a Q2 update, the company noted it was on track to debut topline results for this trial in Stargardt disease in the second quarter of 2027.
Another gene therapy player eyeing this market is Nanoscope Therapeutics, which is taking its rival drug, MCO-010, to Phase III after it significantly improved vision in the Phase II STARLIGHT study (NCT05417126).
Previously, GlobalData managing analyst Sara Reci told Pharmaceutical Technology’s sister publication, Clinical Trials Arena, that functional benefit on visual acuity would offer as a key differentiator in the increasingly competitive Stargardt space.
